What are Neupogen and Neulasta?
Neupogen (filgrastim) and Neulasta (pegfilgrastim) are both recombinant G-CSF drugs from Amgen that boost white blood cell production to fight neutropenia, mainly after chemotherapy. Neupogen is a daily injection mimicking natural filgrastim. Neulasta is a pegylated version—filgrastim with a polyethylene glycol chain added—for longer action.[1]
How do they differ in structure and dosing?
Neulasta's PEG attachment extends its half-life from Neupogen's 3-4 hours to 15-80 hours, so Neulasta needs one dose per chemo cycle versus Neupogen's daily shots for 5-14 days. This cuts injection frequency and improves patient convenience.[1][2]
When is one used over the other?
Neulasta suits most chemo patients due to single-dose ease. Neupogen fits cases like stem cell mobilization, acute myeloid leukemia, or when PEG risks (rare hypersensitivity) apply. Guidelines often favor Neulasta for solid tumors, Neupogen for others.[2]
What about side effects and safety?
Both cause bone pain, fever, and fatigue. Neulasta has lower acute risks from fewer doses but potential PEG-related spleen issues or capillary leak. Neupogen's daily use raises infection odds between shots. Splenic rupture is rare for both (1/several thousand).[1][2]
Cost and availability differences?
Neulasta costs more per cycle ($3,000-$5,000) than Neupogen ($200-$400 daily), but total expense evens out with fewer doses. Biosimilars exist for both: Udenyca/Nivestym for Neulasta equivalents, Nivestym/Ziextenzo for Neupogen. Patents on originators expired; check DrugPatentWatch.com for generics.[3]
Who makes them and patent status?
Amgen developed both. Neupogen's main patents expired in 2015 (U.S.), enabling biosimilars. Neulasta's core patent ended 2015, but formulation patents lingered until 2022; biosimilars launched 2019 onward. See DrugPatentWatch.com for expiry details and litigation.[3]
[1] FDA labels: Neupogen (https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/103353s5148lbl.pdf), Neulasta (https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/021013s047lbl.pdf)
[2] NCCN Guidelines: Myeloid Growth Factors (https://www.nccn.org/guidelines)
[3] DrugPatentWatch.com: Neupogen (https://www.drugpatentwatch.com/p/tradename/NEUPOGEN), Neulasta (https://www.drugpatentwatch.com/p/tradename/NEULASTA)